Preparing For Tivozanib Approval, Aveo Restructures With Staff Cuts
This article was originally published in The Pink Sheet Daily
Executive Summary
The Cambridge, Mass.-based company slows R&D and lays off 17% of its work force, but prepares to build a sales staff as it continues to reap auspicious data on the kidney cancer drug.
You may also be interested in...
Aveo/Astellas’ Tivozanib Bests Nexavar, Barely, In Advanced Kidney Cancer
Aveo/Astellas’ triple VEGF inhibitor tivozanib hit its progression-free survival endpoint of superiority over Onyx/Bayer’s Nexavar (sorafenib), but the question remains whether a three-month PFS advantage can confer first-line market superiority.
Top Partnering Opportunities In Oncology: Broad Efficacy Leads To Broad Appeal
Partner-ready oncology assets cut across diverse fields, including drug conjugates, vaccines and cancer metabolism, with many likely to become part of early-stage deals with shared risk.
Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib
In a worldwide deal excluding Asia, the two companies will split both revenues and development costs 50/50 in North America and Europe.